Gilead Sciences (GILD)
61.40
-1.39 (2.21%)
Upcoming Events
Latest Headlines
Form 10-K GILEAD SCIENCES INC For: Dec 31
February 25, 2021 4:18 PM - SEC Filing
Gilead Sciences to Present at Upcoming Investor Conferences
February 18, 2021 8:01 AM - BizWire
Form SC 13G/A GILEAD SCIENCES INC Filed by: Capital Research Global Investors
February 16, 2021 3:47 PM - SEC Filing
Form SC 13G/A GILEAD SCIENCES INC Filed by: Capital Research Global Investors
February 16, 2021 1:28 PM - SEC Filing
Gilead Sciences and Wake Forest University School of Divinity Partner to Address HIV Epidemic Through Faith-Based Programming and Community Outreach
February 16, 2021 10:30 AM - BizWire
Form 4 GILEAD SCIENCES INC For: Feb 10 Filed by: Wilfong Diane E.
February 11, 2021 5:58 PM - SEC Filing
Form 4 GILEAD SCIENCES INC For: Feb 10 Filed by: Pletcher Brett A
February 11, 2021 5:56 PM - SEC Filing
Gilead's (GILD) Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma
February 10, 2021 5:15 PM - StreetInsider
Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma
February 10, 2021 5:15 PM - BizWire
FibroGen (FGEN), Pliant Therapeutics (PLRX) to Benefit from Galapagos (GLPG)/Gilead (GILD) Discontinued ISABELA Phase 3 Trials in IPF - Citi
February 10, 2021 3:57 PM - StreetInsider
Form SC 13G/A GILEAD SCIENCES INC Filed by: VANGUARD GROUP INC
February 10, 2021 10:59 AM - SEC Filing
Galapagos (GLPG) and Gilead (GILD) Discontinue ISABELA Phase 3 Trials in IPF
February 10, 2021 9:01 AM - StreetInsider
Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF
February 10, 2021 9:00 AM - BizWire
Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF
February 10, 2021 9:00 AM - StreetInsider
Form 4 GILEAD SCIENCES INC For: Feb 06 Filed by: Wilfong Diane E.
February 9, 2021 7:47 PM - SEC Filing
Form 4 GILEAD SCIENCES INC For: Feb 06 Filed by: Pletcher Brett A
February 9, 2021 7:44 PM - SEC Filing
Form 4 GILEAD SCIENCES INC For: Feb 06 Filed by: Dickinson Andrew D
February 9, 2021 7:41 PM - SEC Filing
Kite Appoints Frank Neumann as Worldwide Head of Clinical Development
February 8, 2021 8:00 AM - BizWire
Gilead Sciences (GILD) PT Raised to $84 at Jefferies
February 5, 2021 8:23 AM - StreetInsider
Gilead Sciences (GILD) PT Raised to $67 at BMO Capital
February 5, 2021 6:50 AM - StreetInsider
Gilead Sciences (GILD) PT Lowered to $75 at Cowen
February 5, 2021 6:41 AM - StreetInsider
Gilead Sciences (GILD) PT Raised to $67 at Truist Securities
February 5, 2021 6:40 AM - StreetInsider
Gilead Sciences (GILD) PT Raised to $87 at Morgan Stanley on 4 Catalysts Driving 2021 Revenue Growth
February 5, 2021 3:10 AM - StreetInsider
Form 8-K GILEAD SCIENCES INC For: Feb 04
February 4, 2021 4:05 PM - SEC Filing
Gilead Sciences (GILD) Raises Quarterly Dividend 4.4% to $0.71; 4.3% Yield
February 4, 2021 4:03 PM - StreetInsider
Gilead Sciences (GILD) Tops Q4 EPS by 4c, Offers FY Guidance
February 4, 2021 4:03 PM - StreetInsider
Gilead Sciences Announces 4.4 Percent Increase in First Quarter 2021 Dividend
February 4, 2021 4:02 PM - BizWire
Gilead Sciences Announces Fourth Quarter and Full Year 2020 Financial Results
February 4, 2021 4:01 PM - BizWire
Gilead Sciences (GILD) call put ratio 3.5 calls to 1 put into quarter results and outlook
February 4, 2021 10:24 AM - StreetInsider
Ligand Pharma (LGND) PT Raised to $310 at H.C. Wainwright After Revenue Tops Expectations
February 4, 2021 6:45 AM - StreetInsider
Form 4 GILEAD SCIENCES INC For: Feb 01 Filed by: Pletcher Brett A
February 3, 2021 6:24 PM - SEC Filing
Gilead Sciences (GILD) weekly IV flat into quarter results and outlook
February 3, 2021 10:17 AM - StreetInsider
Gilead and the Human Rights Campaign Will Work Together to Combat HIV Epidemic and Promote Transgender Justice
February 2, 2021 8:00 AM - BizWire
Pre-Open Stock Movers 02/01: (VIE) (THCB) (CDE) Higher; (QTNT) (NNOX) (GME) Lower (more...)
February 1, 2021 9:30 AM - StreetInsider
Gilead Sciences (GILD) to Increase Its Ownership In Arcus Biosciences (RCUS) to 19.5%
February 1, 2021 8:05 AM - StreetInsider
Gilead Sciences (GILD) and Gritstone (GRTS) Announce Pact Utilizing Gritstone's Vaccine Platform Technology for HIV Cure
February 1, 2021 6:20 AM - StreetInsider
Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure
February 1, 2021 6:00 AM - BizWire
Form 4 GILEAD SCIENCES INC For: Jan 28 Filed by: Horning Sandra
January 29, 2021 5:47 PM - SEC Filing
Form SC 13G/A GILEAD SCIENCES INC Filed by: BlackRock Inc.
January 29, 2021 10:00 AM - SEC Filing
Carvana (CVNA), Alphabet (GOOGL), Walmart (WMT) and RingCentral (RNG) Find Their Place in Jefferies' Franchise Pick List
January 29, 2021 9:50 AM - StreetInsider
Form 4 GILEAD SCIENCES INC For: Jan 26 Filed by: Pletcher Brett A
January 28, 2021 8:09 PM - SEC Filing
Form 4 GILEAD SCIENCES INC For: Jan 26 Filed by: Wilfong Diane E.
January 28, 2021 8:07 PM - SEC Filing
Form 4 GILEAD SCIENCES INC For: Jan 26 Filed by: Mercier Johanna
January 28, 2021 8:05 PM - SEC Filing
Form 4 GILEAD SCIENCES INC For: Jan 26 Filed by: Parsey Merdad
January 28, 2021 7:58 PM - SEC Filing
Form 4 GILEAD SCIENCES INC For: Jan 26 Filed by: O'Day Daniel Patrick
January 28, 2021 7:52 PM - SEC Filing
Form 4 GILEAD SCIENCES INC For: Jan 26 Filed by: Dickinson Andrew D
January 28, 2021 7:45 PM - SEC Filing
Form 4 GILEAD SCIENCES INC For: Jan 22 Filed by: Lofton Kevin E
January 25, 2021 1:56 PM - SEC Filing
Gilead Sciences to Release Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 4, 2021
January 21, 2021 4:01 PM - BizWire
Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research
January 19, 2021 8:00 AM - BizWire
Morgan Stanley Upgrades Gilead Sciences (GILD) to Overweight for 2 Reasons
January 19, 2021 12:55 AM - StreetInsider
Gilead Sciences (GILD) Management Meeting Reveals 5 Takeaways and a Path to $75 - Jefferies
January 14, 2021 8:43 AM - StreetInsider
Gilead (GILD) and Vir Biotechnology (VIR) Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus
January 12, 2021 8:05 AM - StreetInsider
Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus
January 12, 2021 8:00 AM - BizWire
Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus
January 12, 2021 8:00 AM - Globe NewsWire
Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus
January 12, 2021 8:00 AM - StreetInsider
Gilead Sciences (GILD) PT Raised to $65 at BMO Capital
January 12, 2021 6:27 AM - StreetInsider
Gilead Sciences (GILD) Remdesivir Sales Will be Short-Lived - Raymond James
January 11, 2021 10:57 AM - StreetInsider
Pre-Open Stock Movers 01/11: (MESO) (LLY) (WBAI) Higher; (MARA) (RIOT) (MSTR) Lower (more...)
January 11, 2021 9:23 AM - StreetInsider
Gilead Sciences (GILD) Raises FY20 Guidance Due to Remdesivir Sales
January 11, 2021 6:07 AM - StreetInsider
Form 8-K GILEAD SCIENCES INC For: Jan 11
January 11, 2021 6:05 AM - SEC Filing
Gilead Sciences Announces Updated 2020 Guidance
January 11, 2021 6:00 AM - BizWire
Form 8-K/A GILEAD SCIENCES INC For: Oct 23
January 6, 2021 5:26 PM - SEC Filing
Gilead Sciences' (GILD) Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors
January 6, 2021 8:10 AM - StreetInsider
Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors
January 6, 2021 8:00 AM - BizWire
Form 4 GILEAD SCIENCES INC For: Dec 30 Filed by: Whitley Richard James
January 4, 2021 1:25 PM - SEC Filing
Form 4 GILEAD SCIENCES INC For: Dec 30 Filed by: Lofton Kevin E
January 4, 2021 1:21 PM - SEC Filing
Guggenheim Upgrades Gilead Sciences (GILD) to Buy
January 4, 2021 6:26 AM - StreetInsider
Gilead Sciences (GILD) Grinds Higher Into Close
December 31, 2020 3:59 PM - StreetInsider
Stocks with Implied Volatility Movement
December 31, 2020 4:34 AM - StreetInsider
Form 4 GILEAD SCIENCES INC For: Nov 23 Filed by: Lofton Kevin E
December 29, 2020 3:09 PM - SEC Filing
Stocks with Implied Volatility Movement
December 28, 2020 4:29 AM - StreetInsider
Stocks with Implied Volatility Movement
December 24, 2020 4:18 AM - StreetInsider
Gilead Sciences (GILD) PT Lowered to $72 at Citi
December 22, 2020 5:37 AM - StreetInsider
Stocks with Implied Volatility Movement
December 22, 2020 4:50 AM - StreetInsider
Gilead Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021
December 21, 2020 4:01 PM - BizWire
Gilead Sciences (GILD) PT Lowered to $62 at Truist Securities
December 17, 2020 5:12 PM - StreetInsider
Gilead Sciences (GILD) PT Lowered to $100 at Oppenheimer
December 17, 2020 7:49 AM - StreetInsider
Gilead Sciences (GILD) PT Lowered to $80 at Piper Sandler
December 16, 2020 9:02 AM - StreetInsider
UPDATE: Gilead Sciences (GILD) PT Lowered to $68 at BofA Securities
December 16, 2020 6:39 AM - StreetInsider
Gilead's (GILD) Kite Tecartus Granted Conditional Marketing Authorization for Treatment of R/R Mantle Cell Lymphoma in Europe
December 16, 2020 6:14 AM - StreetInsider
Gilead Sciences (GILD) PT Lowered to $65 at Credit Suisse
December 16, 2020 4:40 AM - StreetInsider
Gilead Sciences (GILD) IV flat as shares near eight-month high
December 16, 2020 4:32 AM - StreetInsider
Kite’s Tecartus™ (KTE-X19) Granted Conditional Marketing Authorization for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma in Europe
December 16, 2020 3:01 AM - BizWire
Gilead Sciences (GILD), Galapagos NV (GLPG) Amend Development Agreement for Jyselec
December 15, 2020 4:16 PM - StreetInsider
Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)
December 15, 2020 4:15 PM - BizWire
Gilead and Galapagos announce New Commercialization and Development Agreement for Jyseleca® (filgotinib)
December 15, 2020 4:15 PM - StreetInsider
Gilead Sciences (GILD) KOL Call Takeaways on Trodelvy - RBC Capital
December 15, 2020 6:07 AM - StreetInsider
Redburn Reinstates Gilead Sciences (GILD) at Neutral
December 14, 2020 4:44 AM - StreetInsider
Gilead Sciences (GILD) Acquisition of MYR Makes Sense - Morgan Stanley
December 11, 2020 6:42 AM - StreetInsider
Gilead (GILD) Advances Oncology Portfolio With New Data From Phase 3 ASCENT Trial of Trodelvy in Metastatic TNBC
December 10, 2020 4:48 PM - StreetInsider
Gilead Advances Oncology Portfolio With New Data From Phase 3 ASCENT Trial of Trodelvy® in Metastatic Triple Negative Breast Cancer
December 10, 2020 4:48 PM - BizWire
Form 4 GILEAD SCIENCES INC For: Dec 08 Filed by: Bluestone Jeffrey
December 10, 2020 4:11 PM - SEC Filing
Form 3 GILEAD SCIENCES INC For: Dec 07 Filed by: Bluestone Jeffrey
December 10, 2020 4:08 PM - SEC Filing
Gilead Sciences (GILD) call put ratio 2.6 calls to 1 put into FDA panel votes on Pfizer’s (PFE) Covid vaccine
December 10, 2020 10:02 AM - StreetInsider
Intercept Pharma (ICPT) on Watch on Chatter
December 10, 2020 9:49 AM - StreetInsider
Gilead Sciences to Acquire MYR GmbH
December 10, 2020 9:20 AM - PR NewsWire
Gilead Sciences (GILD) to Acquire MYR GmbH in Deal Valued at Over 1.15 Billion Euro
December 10, 2020 8:01 AM - StreetInsider
Gilead Sciences to Acquire MYR GmbH
December 10, 2020 8:00 AM - BizWire
Gilead Announces Racial Equity Community Impact Fund to Support Black Communities Across United States
December 9, 2020 11:00 AM - BizWire
Form 8-K GILEAD SCIENCES INC For: Dec 07
December 8, 2020 4:14 PM - SEC Filing
Gilead Sciences (GILD) Announces Jeffrey A. Bluestone to Board
December 8, 2020 4:11 PM - StreetInsider
Jeffrey A. Bluestone Joins Gilead Sciences’ Board of Directors
December 8, 2020 4:05 PM - BizWire
Pre-Open Stock Movers 12/07: (KODK) (CKH) Higher; (RIDE) (XPEV) (JKS) Lower (more...)
December 7, 2020 9:26 AM - StreetInsider
Matinas BioPharma (MTNB) Announces Collaboration with NIAID to Evaluate Oral Formulations of Gilead's (GILD) Antiviral Remdesivir Utilizing Matinas' LNC Platform Delivery Technology
December 7, 2020 6:37 AM - StreetInsider
Gilead's (GILD) Yescarta Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma
December 7, 2020 6:35 AM - StreetInsider
Gilead's (GILD) Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients
December 7, 2020 6:35 AM - StreetInsider
Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platf
December 7, 2020 6:35 AM - Globe NewsWire
Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platf
December 7, 2020 6:35 AM - StreetInsider
Yescarta® Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma
December 6, 2020 3:00 PM - BizWire
Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients
December 6, 2020 12:30 PM - BizWire
Yescarta® Is First CAR T-cell Therapy to Demonstrate High Response Rates and Durable Clinical Benefit in a Pivotal Indolent Non-Hodgkin Lymphoma Study
December 5, 2020 12:30 PM - BizWire
New Data for TecartusTM Demonstrate Durable Responses at One Year Follow-Up in Relapsed or Refractory Mantle Cell Lymphoma
December 5, 2020 10:00 AM - BizWire
New Four-Year Data Show Long-Term Survival in Patients With Large B-Cell Lymphoma Treated With Yescarta® in ZUMA-1 Trial
December 5, 2020 10:00 AM - BizWire
Full Article List